---
title: "YD Bio launches cancer testing pilot with Numia Health in Canada"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294062286.md"
description: "YD Bio initiated a six-month pilot with Numia Health in British Columbia to establish a cross-border workflow for physician-ordered blood-based cancer testing. The program targets up to 50 patient episodes, with samples analyzed at EG BioMed US’s lab in Washington. The pilot aims to evaluate scalability, logistics, and patient experience for OkaiDx tests. Any future commercial arrangements depend on the pilot's results."
datetime: "2026-07-28T12:01:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294062286.md)
  - [en](https://longbridge.com/en/news/294062286.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294062286.md)
generator: "portal-rs"
---

# YD Bio launches cancer testing pilot with Numia Health in Canada

-   YD Bio launched a six-month pilot with Numia Health to build a cross-border workflow for physician-ordered blood-based cancer testing in British Columbia. \* Pilot targets up to 50 patient episodes in the Lower Mainland, with samples tested at EG BioMed US’s CLIA-certified, CAP-accredited lab in Bothell, Washington. \* Program will evaluate scalability, logistics, operational performance, patient experience for OkaiDx laboratory-developed tests. \* Any broader, non-exclusive commercial arrangement would depend on pilot results, with additional agreements required. \* OkaiDx tests are not cleared or approved by the FDA or Health Canada. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280800PRIMZONEFULLFEED9799174) on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [YDES.US](https://longbridge.com/en/quote/YDES.US.md)

## Related News & Research

- [YD Bio Files First-Half 2026 Results, Reports Improved Equity Position](https://longbridge.com/en/news/297639743.md)
- [YD Bio management commentary cites larger drug, medical product orders driving H1 2026 revenue up to $0.8 million](https://longbridge.com/en/news/297633109.md)
- [BioNTech (BNTX) Halts Cancer Trial, Is The 15% Undervaluation Still Credible?](https://longbridge.com/en/news/297786944.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [BCAL Diagnostics Builds Early Cancer Detection Platform as Test Uptake Grows](https://longbridge.com/en/news/297849557.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**